{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:05:29Z","timestamp":1785859529363,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"The University of Notre Dame Australia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40291-024-00699-w","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T15:03:47Z","timestamp":1709737427000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-5295","authenticated-orcid":false,"given":"Hanh","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Hird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Cardaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat P.","family":"Lenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"699_CR1","unstructured":"American Society of Clinical Oncology (ASCO). Prostate Cancer: Statistics. https:\/\/www.cancer.net\/cancer-types\/prostate-cancer\/statistics. Accessed 6 Apr 2023."},{"issue":"2","key":"699_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13167-019-00169-y","volume":"10","author":"R Sharma","year":"2019","unstructured":"Sharma R. The burden of prostate cancer is associated with human development index: evidence from 87 countries, 1990\u20132016. EPMA J. 2019;10(2):137\u201352. https:\/\/doi.org\/10.1007\/s13167-019-00169-y.","journal-title":"EPMA J"},{"issue":"3","key":"699_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cpet.2021.03.004","volume":"16","author":"R Seifert","year":"2021","unstructured":"Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate cancer theranostics: PSMA targeted therapy. PET Clin. 2021;16(3):391\u20136. https:\/\/doi.org\/10.1016\/j.cpet.2021.03.004.","journal-title":"PET Clin"},{"issue":"1","key":"699_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semradonc.2020.07.004","volume":"31","author":"E O'Dwyer","year":"2021","unstructured":"O\u2019Dwyer E, Bodei L, Morris MJ. The role of theranostics in prostate cancer. Sem Radiat Oncol. 2021;31(1):71\u201382. https:\/\/doi.org\/10.1016\/j.semradonc.2020.07.004.","journal-title":"Sem Radiat Oncol"},{"key":"699_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1006101","author":"AE Harris","year":"2022","unstructured":"Harris AE, Metzler VM, Lothion-Roy J, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Review. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.1006101.","journal-title":"Front Endocrinol"},{"key":"699_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00801","author":"MA Rice","year":"2019","unstructured":"Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Review. Front Oncol. 2019. https:\/\/doi.org\/10.3389\/fonc.2019.00801.","journal-title":"Front Oncol"},{"issue":"2","key":"699_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.euo.2019.01.001","volume":"2","author":"A Farolfi","year":"2019","unstructured":"Farolfi A, Fendler W, Iravani A, et al. Theranostics for advanced prostate cancer: current indications and future developments. Eur Urol Oncol. 2019;2(2):152\u201362. https:\/\/doi.org\/10.1016\/j.euo.2019.01.001.","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"699_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cpet.2021.03.003","volume":"16","author":"IL Alberts","year":"2021","unstructured":"Alberts IL, Seifert R, Rahbar K, Afshar-Oromieh A. Prostate cancer theranostics: from target description to imaging. PET Clin. 2021;16(3):383\u201390. https:\/\/doi.org\/10.1016\/j.cpet.2021.03.003.","journal-title":"PET Clin"},{"issue":"6","key":"699_CR9","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"issue":"6","key":"699_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5489\/cuaj.6817","volume":"15","author":"G Chauss\u00e9","year":"2021","unstructured":"Chauss\u00e9 G, Ben-Ezra N, Stoopler M, et al. Diagnostic performance of (18)F-DCFPyL positron emission tomography\/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis. Can Urol Assoc J. 2021;15(6):173\u20138. https:\/\/doi.org\/10.5489\/cuaj.6817.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"699_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13550-021-00845-z","volume":"11","author":"S Hober\u00fcck","year":"2021","unstructured":"Hober\u00fcck S, L\u00f6ck S, Borkowetz A, et al. Intraindividual comparison of [68\u00a0Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. Eur J Nucl Med Mol Imaging Res. 2021;11(1):109. https:\/\/doi.org\/10.1186\/s13550-021-00845-z.","journal-title":"Eur J Nucl Med Mol Imaging Res"},{"key":"699_CR12","unstructured":"The jamovi project. jamovi. [Computer Software]. https:\/\/www.jamovi.org. Accessed 4 July 2023."},{"issue":"21","key":"699_CR13","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","volume":"23","author":"NH Bander","year":"2005","unstructured":"Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591\u2013601. https:\/\/doi.org\/10.1200\/JCO.2005.05.160.","journal-title":"J Clin Oncol"},{"issue":"18","key":"699_CR14","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.Ccr-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177\u2013labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182\u201391. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-0231.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"699_CR15","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.32072","volume":"125","author":"ST Tagawa","year":"2019","unstructured":"Tagawa ST, Vallabhajosula S, Christos PJ, et al. Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125(15):2561\u20139. https:\/\/doi.org\/10.1002\/cncr.32072.","journal-title":"Cancer"},{"key":"699_CR16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA-targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med and Biol. 2021;98\u201399:30\u20139. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.04.003.","journal-title":"Nucl Med and Biol"},{"issue":"5","key":"699_CR17","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2967\/jnumed.118.207993","volume":"59","author":"D Ta\u00efeb","year":"2018","unstructured":"Ta\u00efeb D, Foletti J-M, Bardi\u00e8s M, Rocchi P, Hicks RJ, Haberkorn U. PSMa-targeted radionuclide therapy and salivary gland toxicity: why does it matter? J Nucl Med. 2018;59(5):747\u20138. https:\/\/doi.org\/10.2967\/jnumed.118.207993.","journal-title":"J Nucl Med"},{"key":"699_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","volume":"123","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol\/Hematol. 2018;123:42\u201351. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.003.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"11","key":"699_CR19","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00259-015-3083-9","volume":"42","author":"U Eberlein","year":"2015","unstructured":"Eberlein U, Nowak C, Bluemel C, et al. DNA damage in blood lymphocytes in patients after 177Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2015;42(11):1739\u201349. https:\/\/doi.org\/10.1007\/s00259-015-3083-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"suppl_1","key":"699_CR20","doi-asserted-by":"publisher","first-page":"S702","DOI":"10.1093\/ofid\/ofx163.1882","volume":"4","author":"C Terrones","year":"2017","unstructured":"Terrones C, Specht L, Maraldo MV, Lundgren J, Helleberg M. Lymphopenia after radiotherapy and risk of infection. Open Forum Infect Dis. 2017;4(suppl_1):S702\u2013S702. https:\/\/doi.org\/10.1093\/ofid\/ofx163.1882.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"699_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.26887","volume":"14","author":"G Swanson","year":"2022","unstructured":"Swanson G, Hammonds K. Long-term effects of radiation on lymphocytes and risk of opportunistic infections. Cureus. 2022;14(7): e26887. https:\/\/doi.org\/10.7759\/cureus.26887.","journal-title":"Cureus."},{"issue":"2","key":"699_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13566-019-00391-1","volume":"8","author":"MA D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea MA, Reddy GK. The systemic immunostimulatory effects of radiation therapy producing overall tumor control through the abscopal effect. J Rad Oncol. 2019;8(2):143\u201356. https:\/\/doi.org\/10.1007\/s13566-019-00391-1.","journal-title":"J Rad Oncol"},{"issue":"7","key":"699_CR23","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","volume":"10","author":"SC Formenti","year":"2009","unstructured":"Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(09)70082-8.","journal-title":"Lancet Oncol"},{"key":"699_CR24","doi-asserted-by":"publisher","first-page":"1060922","DOI":"10.3389\/fmed.2022.1060922","volume":"9","author":"O Sartor","year":"2022","unstructured":"Sartor O, Baghian A. Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts. Front Med (Lausanne). 2022;9:1060922. https:\/\/doi.org\/10.3389\/fmed.2022.1060922.","journal-title":"Front Med (Lausanne)."},{"issue":"5","key":"699_CR25","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.euf.2021.06.006","volume":"8","author":"B Sheehan","year":"2022","unstructured":"Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific membrane antigen biology in lethal prostate cancer and its therapeutic implications. Eur Urol Focus. 2022;8(5):1157\u201368. https:\/\/doi.org\/10.1016\/j.euf.2021.06.006.","journal-title":"Eur Urol Focus"},{"issue":"9","key":"699_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19(9):589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"699_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.117.191874","volume":"59","author":"NM Donin","year":"2018","unstructured":"Donin NM, Reiter RE. Why targeting PSMA is a game changer in the management of prostate cancer. J Nucl Med. 2018;59(2):177\u201382. https:\/\/doi.org\/10.2967\/jnumed.117.191874.","journal-title":"J Nucl Med"},{"issue":"4","key":"699_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1169","volume":"2","author":"S Sengupta","year":"2019","unstructured":"Sengupta S, Asha Krishnan M, Chattopadhyay S, Chelvam V. Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. Cancer Rep (Hoboken). 2019;2(4): e1169. https:\/\/doi.org\/10.1002\/cnr2.1169.","journal-title":"Cancer Rep (Hoboken)."},{"issue":"12","key":"699_CR29","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-024-00699-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-024-00699-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T09:47:11Z","timestamp":1714729631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-024-00699-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1007\/s40291-024-00699-w","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"1 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NL is a scientific advisor to Telix Pharmaceuticals and a principal investigator on the ProstACT trials using Lu-TLX591. No other authors (KH, JC, SS and HN) have relevant financial or non-financial interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No funds, grants or other support was received for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Low or negligible risk research approval by St Vincent\u2019s Hospital Human Research Ethics Committee (HREC), ETH00247 in accordance with the National Statement on Ethical Conduct in Human Research, 2007 (NHMRC). Cross-institutional approval reviewed by the University of Notre Dame HREC, 2023-052F in accordance with the National Statement on Ethical Conduct in Human Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All authors contributed to the study\u2019s conception and design. Material preparation, data collection and analysis were performed by NL, KH, JC, SS, and HN. The first draft of the manuscript was written by HN and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}},{"value":"Not applicable","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}